Abstract:
BACKGROUND:HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC). METHODS:Between April 2002 and June 2005, twenty-two patients with metastatic breast cancer with the presence of overexpression or amplification of HER2-/neu, all pre-treated with trastuzumab plus other cytotoxics, were treated with trastuzumab (6 mg/kg every three weeks) in combination with metronomic chemotherapy (MTX 2.5 mg, bid on Day 1 and Day 4 every week) and CTX (50 mg daily) (CM). RESULTS:The 22 enrolled patients are evaluable: most had an ECOG performance status of 0 (17 pts), and all were pre-treated with chemotherapy for metastatic disease; 14 had progressive disease at study entry, and 11 had progressive disease during the last trastuzumab therapy. Metastatic sites included: lung (5 pts), liver (14 pts), bone (12 pts), lymph nodes (8 pts), central nervous system (CNS) (9 pts). We observed 4 partial remission (PR) (18%, 95% CI 5-40%), 10 stable disease (SD) (46%, 95% CI 24-68%), and 8 PD (36%, CI 17-59%). The clinical benefit (RP plus RC plus SD for > or = 24 weeks) in all pts and in pts with disease resistant to previous trastuzumab therapy were 46% (95% CI, 24-68%) and 27% (95% CI, 6-61%), respectively. Median time to progression was 6 months and median duration of treatment was 5 months (range, 0,7 to 18.4 months and range, 1 to 18 months, respectively). Overall clinical toxicity was generally mild. Grade > or =2 reversible liver toxicity and leukopenia were reported in 5 and 3 pts, respectively. CONCLUSION:The combination of trastuzumab and metronomic chemotherapy is effective and minimally toxic in advanced breast cancer patients. The efficacy observed in patients with disease resistant to trastuzumab supports the need of larger trial to confirm a role of this combination to delay acquired trastuzumab resistance.
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Orlando L,Cardillo A,Ghisini R,Rocca A,Balduzzi A,Torrisi R,Peruzzotti G,Goldhirsch A,Pietri E,Colleoni Mdoi
10.1186/1471-2407-6-225subject
Has Abstractpub_date
2006-09-15 00:00:00pages
225issn
1471-2407pii
1471-2407-6-225journal_volume
6pub_type
临床试验,杂志文章相关文献
BMC CANCER文献大全abstract:BACKGROUND:The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secon...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/1471-2407-10-642
更新日期:2010-11-23 00:00:00
abstract:BACKGROUND:Angiogenesis is generally involved during the cancer development and hematogenous metastasis. Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are considered to have an important role in tumor-associated angiogenesis. However, the effects of simultaneously targeting on VE...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2834-8
更新日期:2016-10-12 00:00:00
abstract:BACKGROUND:Free flap-mediated gene therapy in the tumor bed following surgical resection is a promising approach in cancer targeted treatment of residual disease. We investigated the selective killing efficacy of a lentivirus-mediated cytosine deaminase-thymidine kinase (CDglyTK) gene in transplanted breast cancer deli...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-6111-5
更新日期:2019-09-14 00:00:00
abstract:BACKGROUND:The human pancreatic cancer cell line A818-6 can be grown in vitro either as a highly malignant, undifferentiated monolayer (ML) or as three-dimensional (3D) single layer hollow spheres (HS) simulating a benign, highly differentiated, duct-like pancreatic epithelial structure. This characteristic allowing A8...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-06773-w
更新日期:2020-03-30 00:00:00
abstract:BACKGROUND:Embryonic Liver Fodrin (ELF) is an adaptor protein of transforming growth factor (TGF-β) signaling cascade. Disruption of ELF results in mislocalization of Smad3 and Smad4, leading to compromised TGF-β signaling. c-Myc is an important oncogenic transcription factor, and the disruption of TGF-β signaling prom...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4379-5
更新日期:2018-04-24 00:00:00
abstract:BACKGROUND:The objective of this study was to evaluate the efficacy and toxicity of infusional 5-fluorouracil (5-FU), folinic acid and oxaliplatin (modified FOLFOX-6) in patients with advanced gastric cancer (AGC), as first-line palliative combination chemotherapy. We also analyzed the predictive or prognostic value of...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-148
更新日期:2008-05-27 00:00:00
abstract:BACKGROUND:Knowledge about the expression and thus a role of enzymes that produce endogenous H2S - cystathionine-β-synthase, cystathionine γ-lyase and mercaptopyruvate sulfurtransferase - in renal tumors is still controversial. In this study we aimed to determine the expression of these enzymes relatively to the expres...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4508-1
更新日期:2018-05-24 00:00:00
abstract:BACKGROUND:MicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is the case with members of the miR-200 family, which are the primary regulators of the epithelial to mesenchymal transition and have been reported to act as both oncogenes and tumor suppressors. This study assessed...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-72
更新日期:2013-02-08 00:00:00
abstract:BACKGROUND:Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD). METHODS:In this study, we evaluated DPYD promoter methylation through quantitative methylation-specific PCR a...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-470
更新日期:2010-09-01 00:00:00
abstract:BACKGROUND:The length of interval between successive childbirths (birth interval) might influence the incidence of breast cancer, either by stimulating or by inhibiting the factors that are responsible for the initiation of breast cancer or its early development. METHODS:This is a case-control study nested in a cohort...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5404-z
更新日期:2019-03-04 00:00:00
abstract:BACKGROUND:Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-90
更新日期:2011-03-02 00:00:00
abstract:BACKGROUND:CD133 (prominin-1) is widely believed to be a cancer stem cell marker in various solid tumor types, and CD133 has been correlated with tumor-initiating capacity. Recently, the nuclear location of CD133 expression in tumors has been discussed, but hepatocellular carcinoma (HCC) has not been included in these ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3460-9
更新日期:2017-07-07 00:00:00
abstract:BACKGROUND:Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer p...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2267-4
更新日期:2016-03-19 00:00:00
abstract:BACKGROUND:Prognostic factors aid in the stratification and treatment of cancer. This study evaluated prognostic importance of tumor infiltrating immune cell in patients with oral squamous cell carcinoma. METHODS:Profiles of infiltrating immune cells and clinicopathological data were available for 78 OSCC patients wit...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3317-2
更新日期:2017-05-26 00:00:00
abstract:BACKGROUND:Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. This stud...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-06865-7
更新日期:2020-04-21 00:00:00
abstract:BACKGROUND:To assess the clinical value of peritoneal washing cytology (PWC) in women with BRCA1 or BRCA2 mutations and women from a family with hereditary breast and/or ovarian cancer (HBOC) undergoing risk-reducing salpingo-oophorectomy (RRSO) in detecting primary peritoneal cancer (PPC) or occult ovarian/fallopian t...
journal_title:BMC cancer
pub_type: 杂志文章,meta分析,评审
doi:10.1186/s12885-015-2011-5
更新日期:2016-01-14 00:00:00
abstract:BACKGROUND:Metastasis is the main cause of death for lung cancer patients. The ex vivo 4D acellular lung model has been shown to mimic this metastatic process. However, the main concern is the model's lack of cellular components of the tumor's microenvironment. In this study, we aim to determine if the intact lung micr...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4358-x
更新日期:2018-04-18 00:00:00
abstract:BACKGROUND:Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4-12% of EGFR mutations and are generally refractory to the 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs). Development of effective therapies for patients with EGFRex20ins mutant non-small-cell ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5820-0
更新日期:2019-06-17 00:00:00
abstract:BACKGROUND:Gastric cancer peritoneal carcinomatosis is a common clinical problem, but there are no suitable large animal models to study this problem. This study was to establish a stable rabbit peritoneal carcinomatosis model of gastric cancer using VX2 tumor, and analyze the clinico-pathological features. METHODS:VX...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-124
更新日期:2010-04-01 00:00:00
abstract:BACKGROUND:Solid tumours are less oxygenated than normal tissues. This is called tumour hypoxia and leads to resistance to radiotherapy and chemotherapy. The molecular mechanisms underlying such resistance have been investigated in a range of tumour types, including the adult brain tumours glioblastoma, yet little is k...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5476-9
更新日期:2019-04-03 00:00:00
abstract:BACKGROUND:The development of non-small cell lung carcinoma proceeds through a series of well-defined pathological steps before the appearance of invasive lung carcinoma. The molecular changes that correspond with pathology changes are not well defined and identification of the molecular events may provide clues on the...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-5-155
更新日期:2005-12-06 00:00:00
abstract:BACKGROUND:Along with the marked increase in early gastric cancer (EGC) in the Eastern countries, there has been an effort to adopt the sentinel node concept in EGC to preserve gastric function and reduce the occurrence of postoperative complications. Based on promising results from a previous quality control study, th...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/s12885-016-2336-8
更新日期:2016-05-31 00:00:00
abstract:BACKGROUND:Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRASmut) and CA 19-9 during adjuvant treatment and follow-...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07736-x
更新日期:2021-01-11 00:00:00
abstract:BACKGROUND:Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central nervous system and other organs. The majority are caused by somatic inactivating mutations or deletions affecting the tumor suppressor locus SMARCB1 [OMIM 601607]. Germ-line SMARCB1 inactivation has been reported in associatio...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-437
更新日期:2009-12-13 00:00:00
abstract:BACKGROUND:Preoperative chemoradiotherapy is the recommended standard of care for patients with local advanced rectal cancer. However, it remains unclear, whether a prolonged time interval to surgery results in an increased perioperative morbidity, reduced TME quality or better pathological response. Aim of this study ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-6538-8
更新日期:2020-01-20 00:00:00
abstract:BACKGROUND:Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) can be as effective as neoadju...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07766-5
更新日期:2021-01-05 00:00:00
abstract:BACKGROUND:About 5-10% of breast cancer is due to inherited disease predisposition. Many previously identified susceptibility factors are involved in the maintenance of genomic integrity. AATF plays an important role in the regulation of gene transcription and cell proliferation. It induces apoptosis by associating wit...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-457
更新日期:2009-12-21 00:00:00
abstract:BACKGROUND:Multi-drug Resistance associated Protein-1 (MRP1) can export chemotherapeutics from cancer cells and is implicated in chemoresistance, particularly as is it known to be up-regulated by chemotherapeutics. Our aims in this study were to determine whether activation of Notch signalling is responsible for chemot...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1625-y
更新日期:2015-09-11 00:00:00
abstract:BACKGROUND:The aim of the trial was to compare two active adjuvant chemotherapy regimens in patients with early stage colorectal cancer (CRC). METHODS:Patients were assigned to oxaliplatin, leucovorin and 5-FU for 12 cycles (group A, FOLFOX6) or oxaliplatin and capecitabine for eight cycles (group B, CAPOX). Primary e...
journal_title:BMC cancer
pub_type: 杂志文章,随机对照试验
doi:10.1186/s12885-015-1406-7
更新日期:2015-05-10 00:00:00
abstract:BACKGROUND:It has been shown in several studies that survival in cancer patients who were operated on by a high-volume surgeon was better. Why then do all patients not benefit from treatment by these experienced surgeons? The aim of our work was to study the hypothesis that in breast cancer, geographical isolation and ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-351
更新日期:2012-08-13 00:00:00